Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A3H2101
Tue, 21.02.2023
aap Implantate AG
Sales: Good start in January 2023 in the U.S. with double-digit sales growth; international distributors confident of sales expansion in 2023
Silver: Restart of human clinical trial after approved clinical trial protocol amendment in April 2023; significant acceleration in patient recruitment expected
Successful start of capital increase with [ … ]
Tue, 21.02.2023
aap Implantate AG
Sales: Good start in January 2023 in the U.S. with double-digit sales growth; international distributors confident of sales expansion in 2023
Silver: Restart of human clinical trial after approved clinical trial protocol amendment in April 2023; significant acceleration in patient recruitment expected
Successful start of capital increase with [ … ]
Tue, 21.02.2023
aap Implantate AG
The Management Board of aap Implantate AG (“aap” or the “Company”) resolved on 21 February 2023 with the approval of the Supervisory Board on the same day on a capital increase against cash contributions out of the authorized capital 2022/I with subscription and oversubscription rights of the shareholders of the Company. aap’s share capital shall b [ … ]
Tue, 21.02.2023
aap Implantate AG
The Management Board of aap Implantate AG (“aap” or the “Company”) resolved on 21 February 2023 with the approval of the Supervisory Board on the same day on a capital increase against cash contributions out of the authorized capital 2022/I with subscription and oversubscription rights of the shareholders of the Company. aap’s share capital shall b [ … ]
Fri, 25.11.2022
aap Implantate AG
aap Implantate AG ("aap" or the "Company") announces that with the recent approval for an amendment to the clinical trial plan by the BfArM and the Ethics Committee, an important step towards accelerating the human clinical trial of the antibacterial silver coating technology developed by aap could be implemented. The changes to the clinical trial [ … ]
Fri, 25.11.2022
aap Implantate AG
aap Implantate AG ("aap" or the "Company") announces that with the recent approval for an amendment to the clinical trial plan by the BfArM and the Ethics Committee, an important step towards accelerating the human clinical trial of the antibacterial silver coating technology developed by aap could be implemented. The changes to the clinical trial [ … ]
Wed, 16.11.2022
aap Implantate AG
Sales: Q3 at EUR 3.0 million (+1 % yoy) and 9M at EUR 8.5 million (‑4 % yoy); US business back on track with significant sales increase of +45 % in Q3
EBITDA: Q3 normalized[1] with EUR ‑0.4 million (reported: EUR ‑0.8 million; Q3/2021: EUR +20 thousand) and 9M with EUR ‑1.5 million (9M/2021: EUR +0.1 million) impacted by revenue decline (9M), s [ … ]
Wed, 16.11.2022
aap Implantate AG
Sales: Q3 at EUR 3.0 million (+1 % yoy) and 9M at EUR 8.5 million (‑4 % yoy); US business back on track with significant sales increase of +45 % in Q3
EBITDA: Q3 normalized[1] with EUR ‑0.4 million (reported: EUR ‑0.8 million; Q3/2021: EUR +20 thousand) and 9M with EUR ‑1.5 million (9M/2021: EUR +0.1 million) impacted by revenue decline (9M), s [ … ]
Tue, 25.10.2022
aap Implantate AG
aap Implantate AG ("aap" or the "Company") achieved slight sales growth in the third quarter in a persistently volatile market environment. According to preliminary figures, aap increased sales by +1 % to EUR 3.0 million (Q3/2021: EUR 3.0 million) in the third quarter of the current year compared to the same period of the previous year. In the firs [ … ]
Tue, 25.10.2022
aap Implantate AG
aap Implantate AG ("aap" or the "Company") achieved slight sales growth in the third quarter in a persistently volatile market environment. According to preliminary figures, aap increased sales by +1 % to EUR 3.0 million (Q3/2021: EUR 3.0 million) in the third quarter of the current year compared to the same period of the previous year. In the firs [ … ]